January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

December 09, 2024

Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit

Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data prese...

The ASCO Post

April 22, 2024

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or ga...

The ASCO Post

May 09, 2024

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

The ASCO Post

September 25, 2019

Advances in Cancer Therapy

Lalith Kumaraswamy, PhD, DABR, discusses advances in cancer therapy. There are recent advances in cancer therapy that show some promise for certain type of cancers.

Roswell Park Comprehensive Cancer Center

May 03, 2023

First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–clau...

The ASCO Post

June 13, 2023

Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding

Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequent...

The ASCO Post

September 25, 2019

Take 2 Aspirin and Call Me in the Morning: Re-evaluating Old Drugs for the Modern Era

Anurag Singh, MD reviews data for the effects of common drugs such as aspirin and beta-blockers in outcomes with radiation for a variety of malignancies.

Roswell Park Comprehensive Cancer Center

September 24, 2025

Endoscopic Surveillance for Barrett’s Esophagus: Two-Year Results

"The burden of Barrett’s surveillance on endoscopic resources can be significant, and it may be appropriate to lengthen the surveillance interval or consider offering at-need endoscopy to well-informed patients."

Conexiant

August 04, 2021

Is Tumor Mutational Burden Predictive of Survival Outcomes in Solid Tumors Treated With Immune Checkpoint Inhibitors?

In a letter to the editor in The New England Journal of Medicine, Benoit Rousseau, MD, PhD, and Michael B. Foote, MD, of Memorial Sloan Kettering Cancer Center (MSK), and colleagues presented evidence...

The ASCO Post